Compare KRMD & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRMD | ADAG |
|---|---|---|
| Founded | 1980 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.3M | 254.4M |
| IPO Year | 2019 | 2020 |
| Metric | KRMD | ADAG |
|---|---|---|
| Price | $4.23 | $3.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $6.50 | ★ $8.25 |
| AVG Volume (30 Days) | ★ 117.5K | 105.7K |
| Earning Date | 05-06-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,127,366.00 | N/A |
| Revenue This Year | $20.32 | N/A |
| Revenue Next Year | $17.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.23 | N/A |
| 52 Week Low | $2.68 | $1.44 |
| 52 Week High | $6.61 | $4.75 |
| Indicator | KRMD | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 53.95 | 53.40 |
| Support Level | $3.87 | $3.31 |
| Resistance Level | $4.34 | $3.99 |
| Average True Range (ATR) | 0.17 | 0.30 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 45.45 | 75.61 |
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.